BCX9930
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complement 3 Glomerulopathy
Conditions
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
Trial Timeline
Feb 18, 2022 → Sep 23, 2022
NCT ID
NCT05162066About BCX9930
BCX9930 is a phase 2 stage product being developed by BioCryst Pharmaceuticals for Complement 3 Glomerulopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05162066. Target conditions include Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy.
Hype Score Breakdown
Clinical
12
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05741346 | Phase 2 | Terminated |
| NCT05162066 | Phase 2 | Terminated |
Competing Products
5 competing products in Complement 3 Glomerulopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CSL040 + Placebo | CSL | Phase 1 | 29 |
| Immunological diagnosis tests | CSL | Pre-clinical | 18 |
| RP-L102 | Rocket Pharmaceuticals | Phase 2 | 29 |
| RP-L102 | Rocket Pharmaceuticals | Phase 1 | 15 |
| RP-L102 | Rocket Pharmaceuticals | Phase 2 | 29 |